Christoph Brackmann bought $232k of NVCR
Chief Financial Officer at NovoCure Ltd. 20,000 shares at an average of $11.59, traded Jul 29, 2025, filed Jul 30, 2025.
Score components
- +22RoleCFO
- +13Trade size$232k at market
- +3Relative to holdingsHoldings up 17%
- +18Price context0% above the 52-week low; 66% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +12.4%, 3m +22.9%, 6m +14.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001562180-25-005572, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 29, 2025 | POpen-market purchase Ordinary Shares | +10,000 | $11.63 | $116k | 131,150 | Jul 30, 2025 |
| Jul 29, 2025 | POpen-market purchase Ordinary Shares | +5,000 | $11.60 | $58k | 136,150 | Jul 30, 2025 |
| Jul 29, 2025 | POpen-market purchase Ordinary Shares | +5,000 | $11.50 | $58k | 141,150 | Jul 30, 2025 |
Related signals
Other insiders at NovoCure Ltd and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 60Notable | NovoCure Ltd | Frank X Leonard Chief Executive Officer | $615k 34,273 shares | -7% | |
| 41Moderate | NovoCure Ltd | Jeryl L Hilleman director | $46k 2,945 shares | -18% | |
| 41Moderate | NovoCure Ltd | David Hung director | $46k 2,945 shares | -13% | |
| 36Weak | NovoCure Ltd | Gabriel Leung director | $46k 2,945 shares | -3% | |
| 36Weak | NovoCure Ltd | W Anthony Vernon director | $46k 2,945 shares | -1% | |
| 41Moderate | NovoCure Ltd | Timothy J Scannell director | $46k 2,945 shares | -17% | |
| 41Moderate | NovoCure Ltd | Allyson J Ocean director | $46k 2,945 shares | -21% | |
| 41Moderate | NovoCure Ltd | Kristin Stafford director | $46k 2,945 shares | -21% | |
| 46Moderate | NovoCure Ltd | Christoph Brackmann Chief Financial Officer | $85k 6,412 shares | -3% | |
| 64Notable | NovoCure Ltd | William F Doyle Executive Chairman | $933k 71,887 shares | -18% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.